Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
HEADLINES:
ALL
|
PRO
|
FOCUS
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
PR Newswire (May 8, 2013)
-
PR Newswire (Apr 26, 2013)
-
PR Newswire (Mar 11, 2013)
-
PR Newswire (Mar 1, 2013)
-
PR Newswire (Feb 14, 2013)
-
PR Newswire (Feb 7, 2013)
-
PR Newswire (Jan 30, 2013)
-
PR Newswire (Dec 12, 2012)
To learn more about Seeking Alpha Pro, click here.
-
6 Liquid Small-Cap Healthcare Stocks Projected For Strong GrowthZetaKap • Thu, Aug 30, 2012
-
Avanir's CEO Discusses Q4 2011 Results - Earnings Call TranscriptMon, Dec 12, 2011 • 1 Comment
-
PR Newswire (May 8, 2013)
-
PR Newswire (Apr 26, 2013)
-
PR Newswire (Mar 11, 2013)
-
PR Newswire (Mar 1, 2013)
-
PR Newswire (Feb 14, 2013)
-
PR Newswire (Feb 7, 2013)
-
PR Newswire (Jan 30, 2013)
-
PR Newswire (Dec 12, 2012)
-
PR Newswire (Nov 21, 2012)
-
PR Newswire (Sep 20, 2012)
-
PR Newswire (Sep 14, 2012)
-
PR Newswire (Sep 5, 2012)
-
at Fox Business (Aug 30, 2012)
AVNR vs. ETF Alternatives
Company Description
AVANIR is a pharmaceutical company focused on acquiring, developing and commercializing novel therapeutic products for the treatment of central nervous system disorders. Our lead product candidate, Zenviatm (dextromethorphan hydrobromide/quinidine sulfate), has successfully completed three Phase... More







